Ontology type: schema:ScholarlyArticle Open Access: True
2022-05-06
AUTHORSJacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch, Shaita Picard, Erika Hamilton, Suzanne Jones, Howard Burris, David Spigel
ABSTRACTBackgroundThe National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence. Biomarkers such as Ki-67 potentially have most value in patients with intermediate risk factors, such as involvement of 1–3 positive nodes. This study evaluated the use of Ki-67 testing and treatment patterns in patients with HR+, human epidermal growth factor receptor 2-negative early breast cancer.MethodsThis was an observational retrospective cohort study of patients with electronic medical records from January 2010 to August 2018 treated for HR+, HER2− early breast cancer at Sarah Cannon sites in the United States (US). Overall, 567 patients were randomly selected after using the eligibility criteria: female or male ≥18 years, without distant metastases, and with available physician and pathology reports. Multivariable logistic regression was used to investigate factors predicting Ki-67 testing and test results. Descriptive analyses were applied to treatment patterns.ResultsMultivariable logistic regression analyses found no clinical or pathological factors that predicted whether Ki-67 testing had been ordered by physicians. Of all tested patients (N = 130), having Grade-2 tumors (OR, 7.95 [95% CI: 2.05, 30.9]; p = 0.0027) or Grade-3 tumors (OR, 95.3 [95% CI, 11.9, 760.7]; p < 0.001) at initial diagnosis was a predictor of high Ki-67 expression (≥20%). Ki-67 expression was tested in 23.6% (61/258) of patients with 1–3 positive nodes; 54.1% of them (33/61) had high Ki-67 expression (≥20%). While having a higher grade tumor predicted high Ki-67 (≥20%), 28.6% of patients with Grade-1 tumors also had high Ki-67 expression. Neo-adjuvant therapy was received by 16.0% of patients (91/567), most of whom (66/91; 72.5%) received CT alone. Adjuvant therapy, either endocrine and/or chemotherapy, was received by 92.6% (525/567) of patients and by 67.0% (61/91) of those who received neo-adjuvant therapy. Most (428/525, 81.5%) received ET in the adjuvant treatment setting.ConclusionsHigh grade tumors predicted high Ki-67 (≥20%) expression, but Ki-67 testing was not widely used in these US patients. Most HR+, HER2− early breast cancers were treated with adjuvant ET, with or without CT. More... »
PAGES502
http://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6
DOIhttp://dx.doi.org/10.1186/s12885-022-09557-6
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1147688001
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/35524219
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biomarkers, Tumor",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Breast Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Chemotherapy, Adjuvant",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ki-67 Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptor, ErbB-2",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Receptors, Progesterone",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "United States",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK",
"id": "http://www.grid.ac/institutes/grid.418786.4",
"name": [
"Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK"
],
"type": "Organization"
},
"familyName": "Brown",
"givenName": "Jacqueline",
"id": "sg:person.014456706621.28",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456706621.28"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Eli Lilly and Company, Indianapolis, IN, USA",
"id": "http://www.grid.ac/institutes/grid.417540.3",
"name": [
"Eli Lilly and Company, Indianapolis, IN, USA"
],
"type": "Organization"
},
"familyName": "Scardo",
"givenName": "Savannah",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Eli Lilly and Company, Indianapolis, IN, USA",
"id": "http://www.grid.ac/institutes/grid.417540.3",
"name": [
"Eli Lilly and Company, Indianapolis, IN, USA"
],
"type": "Organization"
},
"familyName": "Method",
"givenName": "Michael",
"id": "sg:person.07352437521.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07352437521.03"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Genospace, Boston, MA, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Genospace, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "Schlauch",
"givenName": "Dan",
"id": "sg:person.010621214353.66",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621214353.66"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Genospace, Boston, MA, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Genospace, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "Misch",
"givenName": "Amanda",
"id": "sg:person.015646564331.17",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015646564331.17"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Genospace, Boston, MA, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Genospace, Boston, MA, USA"
],
"type": "Organization"
},
"familyName": "Picard",
"givenName": "Shaita",
"id": "sg:person.014253623331.40",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014253623331.40"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Tennessee Oncology, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.492963.3",
"name": [
"Sarah Cannon, Nashville, TN, USA",
"Tennessee Oncology, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Hamilton",
"givenName": "Erika",
"id": "sg:person.01315576133.11",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315576133.11"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sarah Cannon, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.419513.b",
"name": [
"Sarah Cannon, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Jones",
"givenName": "Suzanne",
"id": "sg:person.014751065647.13",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014751065647.13"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Tennessee Oncology, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.492963.3",
"name": [
"Sarah Cannon, Nashville, TN, USA",
"Tennessee Oncology, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Burris",
"givenName": "Howard",
"id": "sg:person.01207006231.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207006231.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Tennessee Oncology, Nashville, TN, USA",
"id": "http://www.grid.ac/institutes/grid.492963.3",
"name": [
"Sarah Cannon, Nashville, TN, USA",
"Tennessee Oncology, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Spigel",
"givenName": "David",
"id": "sg:person.01203145131.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203145131.14"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/bcr2607",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009736506",
"https://doi.org/10.1186/bcr2607"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-016-3950-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034857407",
"https://doi.org/10.1007/s10549-016-3950-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12916-015-0369-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003969537",
"https://doi.org/10.1186/s12916-015-0369-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/s41416-019-0656-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1122986074",
"https://doi.org/10.1038/s41416-019-0656-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10549-019-05198-9",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1112731714",
"https://doi.org/10.1007/s10549-019-05198-9"
],
"type": "CreativeWork"
}
],
"datePublished": "2022-05-06",
"datePublishedReg": "2022-05-06",
"description": "BackgroundThe National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence. Biomarkers such as Ki-67 potentially have most value in patients with intermediate risk factors, such as involvement of 1\u20133 positive nodes. This study evaluated the use of Ki-67 testing and treatment patterns in patients with HR+, human epidermal growth factor receptor 2-negative early breast cancer.MethodsThis was an observational retrospective cohort study of patients with electronic medical records from January 2010 to August 2018 treated for HR+, HER2\u2212 early breast cancer at Sarah Cannon sites in the United States (US). Overall, 567 patients were randomly selected after using the eligibility criteria: female or male \u226518\u2009years, without distant metastases, and with available physician and pathology reports. Multivariable logistic regression was used to investigate factors predicting Ki-67 testing and test results. Descriptive analyses were applied to treatment patterns.ResultsMultivariable logistic regression analyses found no clinical or pathological factors that predicted whether Ki-67 testing had been ordered by physicians. Of all tested patients (N\u2009=\u00a0130), having Grade-2 tumors (OR, 7.95 [95% CI: 2.05, 30.9]; p\u2009=\u20090.0027) or Grade-3 tumors (OR, 95.3 [95% CI, 11.9, 760.7]; p\u2009<\u20090.001) at initial diagnosis was a predictor of high Ki-67 expression (\u226520%). Ki-67 expression was tested in 23.6% (61/258) of patients with 1\u20133 positive nodes; 54.1% of them (33/61) had high Ki-67 expression (\u226520%). While having a higher grade tumor predicted high Ki-67 (\u226520%), 28.6% of patients with Grade-1 tumors also had high Ki-67 expression. Neo-adjuvant therapy was received by 16.0% of patients (91/567), most of whom (66/91; 72.5%) received CT alone. Adjuvant therapy, either endocrine and/or chemotherapy, was received by 92.6% (525/567) of patients and by 67.0% (61/91) of those who received neo-adjuvant therapy. Most (428/525, 81.5%) received ET in the adjuvant treatment setting.ConclusionsHigh grade tumors predicted high Ki-67 (\u226520%) expression, but Ki-67 testing was not widely used in these US patients. Most HR+, HER2\u2212 early breast cancers were treated with adjuvant ET, with or without CT.",
"genre": "article",
"id": "sg:pub.10.1186/s12885-022-09557-6",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024632",
"issn": [
"1471-2407"
],
"name": "BMC Cancer",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "22"
}
],
"keywords": [
"high Ki-67 expression",
"early breast cancer",
"Ki-67 expression",
"adjuvant endocrine therapy",
"neo-adjuvant therapy",
"endocrine therapy",
"breast cancer",
"treatment patterns",
"positive nodes",
"grade tumors",
"Ki-67",
"hormone receptor-positive early breast cancer",
"receptor-positive early breast cancer",
"observational retrospective cohort study",
"National Comprehensive Cancer Network",
"real-world retrospective study",
"human epidermal growth factor receptor",
"adjuvant treatment setting",
"retrospective cohort study",
"grade 3 tumors",
"Comprehensive Cancer Network",
"grade 1 tumors",
"risk of recurrence",
"intermediate risk factors",
"multivariable logistic regression",
"grade 2 tumors",
"high Ki-67",
"high-grade tumors",
"ResultsMultivariable logistic regression analysis",
"logistic regression analysis",
"electronic medical records",
"epidermal growth factor receptor",
"adjuvant chemotherapy",
"growth factor receptor",
"adjuvant therapy",
"cohort study",
"surgical excision",
"distant metastasis",
"initial diagnosis",
"US patients",
"retrospective study",
"risk factors",
"medical records",
"primary treatment",
"pathology reports",
"pathological factors",
"patients",
"eligibility criteria",
"Cancer Network",
"chemotherapy",
"available physicians",
"treatment settings",
"tumors",
"therapy",
"cancer",
"logistic regression",
"factor receptor",
"regression analysis",
"United States",
"physicians",
"expression",
"descriptive analysis",
"MethodsThis",
"recurrence",
"testing",
"metastasis",
"excision",
"factors",
"diagnosis",
"biomarkers",
"receptors",
"study",
"endocrine",
"treatment",
"risk",
"predictors",
"involvement",
"report",
"regression",
"patterns",
"years",
"setting",
"use",
"records",
"criteria",
"test results",
"nodes",
"analysis",
"most value",
"sites",
"results",
"values",
"state",
"network"
],
"name": "A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2\u2212 early breast cancer in the United States",
"pagination": "502",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1147688001"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12885-022-09557-6"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"35524219"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12885-022-09557-6",
"https://app.dimensions.ai/details/publication/pub.1147688001"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:25",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_929.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12885-022-09557-6"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'
This table displays all metadata directly associated to this object as RDF triples.
294 TRIPLES
22 PREDICATES
136 URIs
123 LITERALS
18 BLANK NODES